For women with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer, adding a cyclin-dependent kinase (CDK) 4/6 inhibitor to a nonsteroidal aromatase inhibitor (AI) in the first-line setting or fulvestrant in the second-line setting improves progression-free survival and overall response rate. Therefore, combined therapy with a nonsteroidal AI plus a CDK4/6 inhibitor is now a recommended first-line approach for treatment. While each CDK4/6 inhibitor is highly effective, individual agents have different dosing schedules, adverse effects, and potential toxicities that should be considered when choosing an agent for an individual patient.
eNewsletter with interactive benchmarking
After completing this activity, participants should be better able to:
- Describe clinical evidence supporting the use of combination therapy over AI monotherapy
- Evaluate approaches for the use of CDK4/6 inhibitors for HR+/HER– advanced breast cancer, based on clinical trial evidence and patient and disease factors
- Identify side effects of CDK4/6 inhibitors and their appropriate management so that members of the oncology team can more effectively coordinate patient care and promote adherence
Oncology nurse practitioners, physician assistants, and nurses
In support of improving patient care, Continuing Education Alliance is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Nursing contact hours: 1.00, which includes 1.00 hours of pharmacology credit
Nurse planner: Beth Eaby-Sandy, MSN, CRNP, OCN, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania
This program has been reviewed and is approved for a maximum of 1.0 AAPA Category 1 CME credits by the AAPA Review Panel. Approval is valid for one year from the issue date of August 15, 2018. Participants may submit the post-test at any time during that period.
This program was planned in accordance with AAPA CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.
This program was cosupported by educational grants from Astellas and Pfizer; Bristol-Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc; Lilly USA, LLC; Merck & Co., Inc.; Sanofi Genzyme; and Taiho Oncology, Inc. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
This activity is supported by an educational grant from Lilly USA, LLC.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Continuing Education Alliance, Practicing Clinicians Exchange, the AAPA, or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Continuing Education Alliance are required to disclose to the audience any significant support or substantial relationships with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and planning committee have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Dr Schwartzberg: consultant: Pfizer.
The Planning Committee for this activity included Ruth Cohen, Warren Beckman, Craig Borders, Leslie Burgess, Kathleen Crowley, Jacqueline Egan, Margaret Inman, Devera Pine, Marie Recine, and Stef Stendardo of Continuing Education Alliance; Lee Schwartzberg, MD, of the University of Tennessee Health Science Center; Beth Eaby-Sandy, MSN, CRNP, OCN, of the University of Pennsylvania; and Jessica Garner, MMS, PA-C, of the University of the Pacific. The members of the Planning Committee and independent reviewer have no relevant relationships to disclose, except for Dr Schwartzberg as noted above and Ms Eaby-Sandy: consultant: AbbVie; speakers bureau: AstraZeneca, Helsinn, Merck, Takeda.
Participants wishing to earn CE/CME credit must:
- Read the eNewsletter in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form online
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 70%.
The estimated time to complete this activity is 1.00 hours.
Release date: August 15, 2018 Expiration date: August 15, 2019
© 2019 Practicing Clinicians Exchange. All Rights Reserved. OPCE92818-7C